Trial Profile
The First-In-Human Trial of the Humanised Monoclonal Antibody NNC 0151-0000-0000 Blocking the C5A Receptor (C5AR)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Sep 2014
Price :
$35
*
At a glance
- Drugs NN 8209 (Primary) ; Anti-C5a monoclonal antibody; Anti-C5a monoclonal antibody
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 09 Jul 2009 New trial record.
- 13 Jun 2009 Interim results were reported at EULAR 2009.